NCT02507479

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Sheba Medical Center · Other Government
• Sex: All
• Age: 18 Years – 68 Years
• Healthy volunteers: Accepted

Summary

The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.

Conditions

• Non Hodgkin Lymphoma
• Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Thiotepa	Chemotherapy given prior to allogeneic stem cell transplantation

Timeline

• Start date: 2015-09-01
• Primary completion: 2017-07-01
• Completion: 2019-07-01
• First posted: 2015-07-24
• Last updated: 2016-04-20

Locations

2 sites across 1 country: Israel